Financial News
Latest News about PFE
Recent news which mentions PFE
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
December 07, 2023
From InvestorPlace
From Motley Fool
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
December 06, 2023
From Benzinga
2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains
December 06, 2023
From Benzinga
Arvinas, Pfizer Plan To Broaden Development Of Breast Cancer Candidate
December 06, 2023
From Benzinga
Diamonds in the Rough: 3 Undervalued Stocks with Huge Upside
December 05, 2023
From InvestorPlace
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
December 05, 2023
From Benzinga
3 Stocks at the Forefront of Personalized Medicine Trend
December 05, 2023
From InvestorPlace
7 Compelling Stocks to Buy That are Sitting at 52-Week Lows
December 05, 2023
From InvestorPlace
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
December 04, 2023
From Benzinga
Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk’s Ozempic
December 04, 2023
From MarketWatch
Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes
December 02, 2023
Tickers
PFE
From Motley Fool
An Important History Lesson for Gene-Editing Investors
December 02, 2023
From Motley Fool
5 Top Stocks to Buy Before 2024
December 02, 2023
From Motley Fool
Stocks, Gold, Bonds Rally Further, Dollars Tumbles As Traders Anticipate Fed Cuts: What's Driving Markets Friday?
December 01, 2023
From Benzinga
Why Is Hub Cyber Security (HUBC) Stock Up 30% Today?
December 01, 2023
From InvestorPlace
Why Is Altimmune (ALT) Stock Up 43% Today?
December 01, 2023
From InvestorPlace
Pfizer Layoffs 2023: What to Know About the Latest PFE Job Cuts
December 01, 2023
From InvestorPlace
From Benzinga
Tale Of Two Investigational Obesity Drugs: Altimmune Stock Jumps, While Pfizer Trades Lower
December 01, 2023
From Benzinga
This Twice Daily Weight Loss Drug Has Adverse Side Effects And Pfizer Wants To Discontinue It
December 01, 2023
Tickers
PFE
From Benzinga
From MarketWatch
Billionaire Favorites: 3 Ultra-High Yield Stocks the Elite Love
November 30, 2023
From InvestorPlace
3 Synthetic Biology Stocks Likely to Mint New Millionaires
November 29, 2023
From InvestorPlace
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
November 28, 2023
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.